Ionis Pharmaceuticals, Inc.
MODULATORS OF IRF4 EXPRESSION
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF4 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with IRF4.
Status:
Application
Type:
Utility
Filling date:
1 Mar 2019
Issue date:
11 Feb 2021